PHARMA MAR, S.A. «12345...» Page 5 out of 23 28/02/2024 13:05 PHARMA MAR, S.A. Annual corporate governance report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2023 Register number: 26924 28/02/2024 12:09 PHARMA MAR, S.A. Other relevant information - On business and financial situation The Company reports draw up of the Annual Financial Statements 2023, a proposal for a dividend, and a conference call with analysts and investors. Register number: 26916 28/02/2024 12:02 PHARMA MAR, S.A. On business and financial situation The Company sends press release regarding year 2023 results together with financial report. Register number: 26915 28/02/2024 11:57 PHARMA MAR, S.A. Annual financial reports and audit reports La sociedad remite el Informe Financiero Anual del ejercicio 2023 Register number: 26914 28/02/2024 11:39 PHARMA MAR, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del segundo semestre de 2023 Register number: 26912 31/01/2024 19:05 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from January 1 to January 31, 2024. Ending of the Acquisition of Treasury Shares and resumption of the liquidity contract. Register number: 26379 30/01/2024 17:35 PHARMA MAR, S.A. On corporate governance The Company informs of changes in the chairmanship of the Appointments and Compensation and Sustainability Committee. Register number: 26362 08/01/2024 17:37 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from December 1 to December 31, 2023. Register number: 26121 18/12/2023 08:26 PHARMA MAR, S.A. On business and financial situation Sylentis, a subsidiary of Pharma Mar, announces that the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint. Register number: 25836 12/12/2023 14:33 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Hong Kong. Register number: 25763 Page 5 out of 23 «12345...»
